Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
BACKGROUND OF THE INVENTION
This invention relates to methods, pharmaceutical compositions and kits comprising an aldose reductase inhibitor (ARI), a prodrug thereof or a pharmaceutically acceptable salt of said ARI or said prodrug and a selective serotonin reuptake inhibitor (SSRI), a prodrug
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
All patents, patent applications and publications cited herein are hereby incorporated by reference in their entirety. The disclosures of these publications in their entireties are hereby incorporated by reference into this application in order to more fully describe the state of the art as known to
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
All patents, patent applications and publications cited herein are hereby incorporated by reference in their entirety. The disclosures of these publications in their entireties are hereby incorporated by reference into this application in order to more fully describe the state of the art as known to
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
All patents, patent applications and publications cited herein are hereby incorporated by reference in their entirety. The disclosures of these publications in their entireties are hereby incorporated by reference into this application in order to more fully describe the state of the art as known to
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
FIELD OF THE INVENTION
The present invention relates to novel compounds and pharmaceutical compositions thereof, and methods for promoting healthy aging of skin, the treatment of skin disorders, the treatment of cardiovascular disorders, the treatment of renal disorders, the treatment of
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
All patents, patent applications and publications cited herein are hereby incorporated by reference in their entirety. The disclosures of these publications in their entireties are hereby incorporated by reference into this application in order to more fully describe the state of the art as known to
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
BACKGROUND OF THE INVENTION
This invention relates to methods, pharmaceutical compositions and kits comprising an aldose reductase inhibitor (ARI), a prodrug thereof or a pharmaceutically acceptable salt of said ARI or said prodrug and a selective cyclooxygenase-2 (COX-2) inhibitor, a prodrug
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
BACKGROUND OF THE INVENTION
This invention relates to pharmaceutical combinations of a cholesteryl ester transfer protein (CETP) inhibitor or a pharmaceutically acceptable salt thereof; and an antihypertensive agent or a pharmaceutically acceptable salt thereof, optionally in combination with an HMG
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
COMBINATIONS
The present invention relates to a combination, especially a pharmaceutical composition, comprising (a) a PDE 5 inhibitor or a pharmaceutically acceptable salt thereof and (b) at least one active ingredient selected from the group consisting of (i) an anti-diabetic agent; (ii) HMG-Co-A
Korraldage oma huvisid ja hoidke end kursis uudisteuuringute, kliiniliste uuringute ja patentidega
Sisestage sümptom või haigus ja lugege ravimtaimede kohta, mis võivad aidata, tippige ürdi ja vaadake haigusi ja sümptomeid, mille vastu seda kasutatakse. * Kogu teave põhineb avaldatud teaduslikel uuringutel